A world-class specialty pharmaceutical company
Our ambition is to become a leading specialty pharmaceutical company meeting the needs of patients around the world. With our portfolio of respiratory products we’re making good progress towards achieving our goal.
Press Releases
- Circassia Announces Publication of Tudorza® Phase IV ASCENT Study in the Journal of the American Medical Association
- Preliminary Results for the Year Ended 31 December 2018
- Circassia Announces FDA Approval of Duaklir® for Maintenance Treatment of Chronic Obstructive Pulmonary Disease
